Trial Profile
Phase II study to evaluate efficacy and safety of retherapy with bendamustine and rituximab regimens in patients with relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms B-SRIM
- 15 May 2014 New trial record